{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:07:10Z","timestamp":1793614030664,"version":"4.5.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation Fleurette Wagemakers","award":["La Soci\u00e9t\u00e9 Acad\u00e9mique de Gen\u00e8ve"],"award-info":[{"award-number":["La Soci\u00e9t\u00e9 Acad\u00e9mique de Gen\u00e8ve"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>In SLE, heterogeneous clinical expression and activity may reflect diverse pathogenic and\/or effector mechanisms. We investigated SLE heterogeneity by assessing the expression of three gene sets representative of type I IFN (IFN-I), polymorphonuclear neutrophil (PMN) and plasmablast (PB) signatures in a well-characterized, multidisciplinary cohort of SLE patients. We further assessed whether individual gene products could be representative of these three signatures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Whole blood, serum and clinical data were obtained from 140 SLE individuals. Gene expression was assessed by NanoString technology, using a panel of 37 probes to compute six IFN-I, one PMN and one PB scores. Protein levels were measured by ELISA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Depending on the score, 45\u201350% of SLE individuals showed high IFN-I gene expression. All six IFN-I scores were significantly associated with active skin involvement, and two of six were associated with arthritis. IFN-induced Mx1 protein (MX1) level was correlated with IFN-I score (P &amp;lt; 0.0001) and associated with a similar clinical phenotype. In all, 25% of SLE individuals showed high PMN gene expression, associated with SLE fever, serositis, leukopoenia and glucocorticoid use. PB gene expression was highly affected by immunosuppressant agents, with no association with SLE features. Combined IFN-I and PMN gene scores were significantly associated with high disease activity and outperformed anti-dsDNA and anti-C1q autoantibody and complement levels for predicting SLE activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IFN-I and PMN gene scores segregate with distinct SLE clinical features, and their combination may identify high disease activity. MX1 protein level performed similar to IFN-I gene expression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa167","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T16:12:27Z","timestamp":1584634347000},"page":"3468-3478","source":"Crossref","is-referenced-by-count":36,"title":["Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers"],"prefix":"10.1093","volume":"59","author":[{"given":"Fran\u00e7ois","family":"Chasset","sequence":"first","affiliation":[{"name":"Division of Immunology and Allergy, University Hospital and School of Medicine, Geneva"},{"name":"Department of Pathology and Immunology, School of Medicine, Geneva, Switzerland"},{"name":"Facult\u00e9 de M\u00e9decine Sorbonne Universit\u00e9, AP-HP, Service de Dermatologie et Allergologie, Ho\u00f4pital Tenon, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Ribi","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy, University Hospital Center of Lausanne, Lausanne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marten","family":"Trendelenburg","sequence":"additional","affiliation":[{"name":"Laboratory for Clinical Immunology, Department of Biomedicine and Division of Internal Medicine, University Hospital of Basel, Basel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uyen","family":"Huynh-Do","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Inselspital, Bern University Hospital, Bern"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Roux-Lombard","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy, University Hospital and School of Medicine, Geneva"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1956-2607","authenticated-orcid":false,"given":"Delphine S","family":"Courvoisier","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University Hospital and School of Medicine, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Chizzolini","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy, University Hospital and School of Medicine, Geneva"},{"name":"Department of Pathology and Immunology, School of Medicine, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Swiss SLE Cohort Study (SSCS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"2020102707112964800_keaa167-B1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/art.1780250901","article-title":"Interrelationships of HLA-DR, MB, and MT phenotypes, autoantibody expression, and clinical features in systemic lupus erythematosus","volume":"25","author":"Ahearn","year":"1982","journal-title":"Arthritis Rheum"},{"key":"2020102707112964800_keaa167-B2","doi-asserted-by":"crossref","first-page":"e000303","DOI":"10.1136\/lupus-2018-000303","article-title":"10 most important contemporary challenges in the management of SLE","volume":"6","author":"Felten","year":"2019","journal-title":"Lupus Sci Med"},{"key":"2020102707112964800_keaa167-B3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13075-017-1442-6","article-title":"Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review","volume":"19","author":"Gensous","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2020102707112964800_keaa167-B4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.autrev.2017.02.011","article-title":"Organ-specific biomarkers in lupus","volume":"16","author":"Wu","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2020102707112964800_keaa167-B5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"2020102707112964800_keaa167-B6","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/art.40653","article-title":"Stratification of systemic lupus erythematosus patients into three groups of disease activity progression according to longitudinal gene expression","volume":"70","author":"Toro-Dom\u00ednguez","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2020102707112964800_keaa167-B7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/annrheumdis-2018-214379","article-title":"Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity","volume":"78","author":"Panousis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020102707112964800_keaa167-B8","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020102707112964800_keaa167-B9","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/ard.2007.074765","article-title":"Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus","volume":"67","author":"Nikpour","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2020102707112964800_keaa167-B10","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.38628","article-title":"Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures","volume":"66","author":"Chiche","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2020102707112964800_keaa167-B11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41590-019-0386-1","article-title":"Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways","volume":"20","author":"Der","year":"2019","journal-title":"Nat Immunol"},{"key":"2020102707112964800_keaa167-B12","article-title":"Targeting interferons and their pathways in systemic lupus erythematosus","author":"Chasset","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2020102707112964800_keaa167-B13","first-page":"477","article-title":"Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis","volume":"56","author":"Jourde-Chiche","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2020102707112964800_keaa167-B14","doi-asserted-by":"crossref","first-page":"e0196117","DOI":"10.1371\/journal.pone.0196117","article-title":"Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: clinical\/pathologic associations and etiologic mechanisms","volume":"13","author":"Wither","year":"2018","journal-title":"PloS One"},{"key":"2020102707112964800_keaa167-B15","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/art.24557","article-title":"Neutralization of interferon-alpha\/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus","volume":"60","author":"Yao","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2020102707112964800_keaa167-B16","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/0961203309105529","article-title":"Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus","volume":"18","author":"Petri","year":"2009","journal-title":"Lupus"},{"key":"2020102707112964800_keaa167-B17","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/art.34632","article-title":"Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study","volume":"64","author":"McBride","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020102707112964800_keaa167-B18","doi-asserted-by":"crossref","first-page":"e000080","DOI":"10.1136\/lupus-2014-000080","article-title":"Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE","volume":"2","author":"Kennedy","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2020102707112964800_keaa167-B19","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1474-4422(13)70258-8","article-title":"Assessment of interferon-related biomarkers in Aicardi-Gouti\u00e8res syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study","volume":"12","author":"Rice","year":"2013","journal-title":"Lancet Neurol"},{"key":"2020102707112964800_keaa167-B20","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/art.40656","article-title":"Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (medi-551) and correlates with disease activity in systemic lupus erythematosus and chronic obstructive pulmonary disease","volume":"70","author":"Streicher","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2020102707112964800_keaa167-B21","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2020102707112964800_keaa167-B22","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/art.22044","article-title":"Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus","volume":"54","author":"Feng","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2020102707112964800_keaa167-B23","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020102707112964800_keaa167-B24","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"2020102707112964800_keaa167-B25","first-page":"w13990","article-title":"The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland","volume":"144","author":"Ribi","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"2020102707112964800_keaa167-B26","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2020102707112964800_keaa167-B27","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020102707112964800_keaa167-B28","first-page":"5","author":"Breiman","year":"2001"},{"key":"2020102707112964800_keaa167-B29","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"2020102707112964800_keaa167-B30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/art.39950","article-title":"Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two Phase III trials of BAFF blockade with tabalumab","volume":"69","author":"Hoffman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2020102707112964800_keaa167-B31","doi-asserted-by":"crossref","first-page":"R62","DOI":"10.1186\/ar4499","article-title":"T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?","volume":"16","author":"Brkic","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2020102707112964800_keaa167-B32","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1038\/s41598-018-24198-1","article-title":"A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features","volume":"8","author":"El-Sherbiny","year":"2018","journal-title":"Sci Rep"},{"key":"2020102707112964800_keaa167-B33","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1136\/annrheumdis-2018-213386","article-title":"Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status","volume":"77","author":"Md Yusof","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020102707112964800_keaa167-B34","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/art.30187","article-title":"Network analysis of associations between serum interferon-\u03b1 activity, autoantibodies, and clinical features in systemic lupus erythematosus","volume":"63","author":"Weckerle","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2020102707112964800_keaa167-B35","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2133.2012.10825.x","article-title":"The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score","volume":"166","author":"Braunstein","year":"2012","journal-title":"Br J Dermatol"},{"key":"2020102707112964800_keaa167-B36","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1002\/art.24686","article-title":"Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells","volume":"60","author":"Eloranta","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2020102707112964800_keaa167-B37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"key":"2020102707112964800_keaa167-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/7862962","article-title":"Clinical application of a modular genomics technique in systemic lupus erythematosus: progress towards precision medicine","volume":"2016","author":"Zollars","year":"2016","journal-title":"Int J Genomics"},{"key":"2020102707112964800_keaa167-B39","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.40792","article-title":"Monitoring disease activity in systemic lupus erythematosus with single-molecule array digital ELISA quantification of serum interferon-\u03b1","volume":"71","author":"Mathian","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020102707112964800_keaa167-B40","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/rheumatology\/kez078","article-title":"MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis","volume":"58","author":"Huijser","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2020102707112964800_keaa167-B41","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/ard.2008.093146","article-title":"Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus","volume":"68","author":"Landolt-Marticorena","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2020102707112964800_keaa167-B42","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/annrheumdis-2019-215571","article-title":"Ultrasensitive serum interferon-\u03b1 quantification during SLE remission identifies patients at risk for relapse","volume":"78","author":"Mathian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020102707112964800_keaa167-B43","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2020102707112964800_keaa167-B44","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/ard.2009.108043","article-title":"Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis","volume":"69","author":"Lyons","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2020102707112964800_keaa167-B45","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/BOR.0000000000000197","article-title":"The role of neutrophils in the pathogenesis of systemic lupus erythematosus","volume":"27","author":"Smith","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"2020102707112964800_keaa167-B46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1136\/ard.2008.096495","article-title":"HLA-DRhigh\/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus","volume":"69","author":"Jacobi","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2020102707112964800_keaa167-B47","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cyto.2018.10.023","article-title":"Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies","volume":"113","author":"Pescarmona","year":"2019","journal-title":"Cytokine"},{"key":"2020102707112964800_keaa167-B48","doi-asserted-by":"crossref","first-page":"research0034.1","DOI":"10.1186\/gb-2002-3-7-research0034","article-title":"Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes","volume":"3","author":"Vandesompele","year":"2002","journal-title":"Genome Biol"},{"key":"2020102707112964800_keaa167-B49","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jclinepi.2010.11.012","article-title":"Performance of logistic regression modeling: beyond the number of events per variable, the role of data structure","volume":"64","author":"Courvoisier","year":"2011","journal-title":"J Clin Epidemiol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/11\/3468\/34038043\/keaa167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/11\/3468\/34038043\/keaa167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T08:01:04Z","timestamp":1603785664000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/11\/3468\/5831395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,5,6]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa167","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,5,6]]}}}